Arkolith/Insider Trading/STSA/Form 4

Takanashi Ken

Director, 10% OwnerSatsuma Pharmaceuticals, Inc. (STSA) · full profile →Form 4 · filed Jun 8, 2023
Net Buying
Open-Market Buys
$20.1M
Open-Market Sells
$0
Net Open-Market Flow
$20.1M
Transactions
4
1 non-derivative · 3 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Jun 6, 2023Buy(P)22.1M$0.91$20.1M24.8M

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Jun 8, 2023Disposed to issuer(D)30K—$00
Jun 8, 2023Disposed to issuer(D)20K—$00
Jun 8, 2023Disposed to issuer(D)10K—$00

Transaction Codes

P
Open-market purchase
D
Disposition to the issuer

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0000899243-23-014896) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML